Hanil Pharm. Co. faces on critical edge of bankruptcy

Published: 1999-04-08 15:30:00

Updated: 1999-04-08 15:30:00

The management control of Hanil Pharmaceutical company was transferred to Shin Dong-A group as a subsidiary in the general shareholder's meeting last year, but as of Apr. 2 this year the company was unable to pay the draft of 2,100 million Won arrived at the Shinhan Bank, bringing out the most di...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK